Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound

Atherosclerosis

Volumn 211, Issue 1, 2010, Pages 164-169

  Miyoshi, Toru ^a   Onoue, Go ^a   Hirohata, Atsushi ^b   Hirohata, Satoshi ^a   Usui, Shinichi ^c   Hina, Kazuyoshi ^b   Kawamura, Hiroshi ^b   Doi, Masayuki ^d   Kusano, Kengo Fukushima ^a   Kusachi, Shozo ^c   Ninomiya, Yoshifumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b THE SAKAKIBARA HEART INSTITUTE OF OKAYAMA   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Adipocyte; Coronary artery disease; Fatty acid binding protein; Intravascular ultrasound

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID BINDING PROTEIN 4; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ADIPOQ PROTEIN, HUMAN; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN;

AGED; ANGIOCARDIOGRAPHY; AREA UNDER THE CURVE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD DONOR; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; INTRAVASCULAR ULTRASOUND; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; ATHEROSCLEROSIS; BLOOD; COMPLICATION; ECHOGRAPHY; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADIPONECTIN; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 77954310410     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.01.032     Document Type: Article

References (24)

1. Matsuzawa Y., Nakamura T., Shimomura I., Kotani K. Visceral fat accumulation and cardiovascular disease. Obes Res 1995, 3(Suppl. 5):645S-647S.
2. Fortuno A., Rodriguez A., Gomez-Ambrosi J., Fruhbeck G., Diez J. Adipose tissue as an endocrine organ: role of leptin and adiponectin in the pathogenesis of cardiovascular diseases. J Physiol Biochem 2003, 59:51-60.
3. Makowski L., Hotamisligil G.S. Fatty acid binding proteins-the evolutionary crossroads of inflammatory and metabolic responses. J Nutr 2004, 134:2464S-2468S.
4. Boord J.B., Fazio S., Linton M.F. Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr Opin Lipidol 2002, 13:141-147.
5. Kazemi M.R., McDonald C.M., Shigenaga J.K., Grunfeld C., Feingold K.R. Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler Thromb Vasc Biol 2005, 25:1220-1224.
6. Hotamisligil G.S., Johnson R.S., Distel R.J., et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996, 274:1377-1379.
7. Makowski L, Boord J.B., Maeda K., et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001, 7:699-705.
8. Xu A., Wang Y., Xu J.Y., et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006, 52:405-413.
9. Tso A.W., Xu A., Sham P.C., et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 2007, 30:2667-2672.
10. Yeung D.C., Xu A., Cheung C.W., et al. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:1796-1802.
11. Rhee E.J., Lee W.Y., Park C.Y., et al. The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol 2009, 160:165-172.
12. Cabre A., Lazaro I., Girona J., et al. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 2007, 195:e150-158.
13. Mintz G.S., Nissen S.E., Anderson W.D., et al. American College of Cardiology Clinical Expert Consensus Document on Standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001, 37:1478-1492.
14. Nicholls S.J., Tuzcu E.M., Crowe T., et al. Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol 2006, 47:1967-1975.
15. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008;31(Suppl. 1):S12-54.
16. Nissen S.E., Yock P. Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation 2001, 103:604-616.
17. Makowski L., Brittingham K.C., Reynolds J.M., Suttles J., Hotamisligil G.S. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem 2005, 280:12888-12895.
18. Tuncman G., Erbay E., Hom X., et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci USA 2006, 103:6970-6975.
19. Furuhashi M, Tuncman G., Gorgun C.Z., et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007, 447:959-965.
20. Fisher R.M., Eriksson P., Hoffstedt J., et al. Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia 2001, 44:1268-1273.
21. Fisher R.M., Thorne A., Hamsten A., Arner P. Fatty acid binding protein expression in different human adipose tissue depots in relation to rates of lipolysis and insulin concentration in obese individuals. Mol Cell Biochem 2002, 239:95-100.
22. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European action on secondary prevention through intervention to reduce events. Eur Heart J 1997;18:1569-82.
23. Woodward M., Zhang X., Barzi F., et al. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care 2003, 26:360-366.
24. Yamamoto A., Richie G., Nakamura H., et al. Risk factors for coronary heart disease in the Japanese-comparison of the background of patients with acute coronary syndrome in the ASPAC study with data obtained from the general population. Asia-Pacific Collaboration on CHD Risk Factor Intervention study. J Atheroscler Thromb 2002, 9:191-199.